Our science
Everything we do is based on ethical, replicable, transparent research and data—using the highest standards of current scientific methodology.
Unlocking the potential of
nucleosides
We apply our expertise in chemistry and structural biology to modify the ribose moiety of nucleosides and discover novel treatments in oncology and virology.
A brief introduction to nucleosides
Best known as the building blocks of ribonucleic acid (RNA) and deoxyribonucleic acid (DNA), nucleosides consist of either a ribose group or a deoxyribose (sugar) that’s coupled to a nucleobase—adenine A, guanine G, cytidine C, and uracil U or thymine T. They also form cyclic dinucleotides that are important messengers between cells.
We’re recognized for our collective experience in nucleoside biology and our extensive library of unique nucleoside analogs. They can be used to disrupt unwanted viral genetic replication—chemically stopping growth—or to modify immune response to cancer or other pathogens.
Nucleoside analogs have three major advantages over other viral inhibitors, which make them the preferred treatment for all types of infectious diseases (including HIV, HBV, HCV, HSV, and CMV).
The Riboscience Nucleoside Platform
High barrier to
resistance
This correlates with the typically low affinity binding of nucleosides to their target.
High efficacy
This is the result of modifying the viral polymerase product—the viral genome—rather than blocking the viral polymerase itself.
Broad spectrum
of activity
This is caused by targeting the viral polymerase active site, which is highly conserved across different viral strains.
Applying nucleosides to combat human disease
Watch a Riboscience nucleoside analog in action as it chemically stops and blocks undesirable viral RNA in its tracks—thereby preventing replication and spread.
Video of nucleoside analogs blocking viral replication.
Blocking ENPP1 to boost immunity
Watch a Riboscience nucleoside derivative in action as it inhibits ENPP1, unlocking a powerful anti-cancer immune response.
